Related Experiment Videos
Shift in the megakaryocyte ploidy in MDS patients: microcytofluorometry with DAPI staining after destaining of
Y Kobayashi1, S Kimura, K Tanaka
11st Department of Internal Medicine, Kyoto Prefectural University of Medicine.
Abstract:
We applied DAPI (4',6-diamidino-2-phenylindole) staining to the determination of nuclear DNA content in single megakaryocytes in 12 normal subjects and 12 patients with myelodysplastic syndrome (MDS). After the megakaryocytes had been identified on Wright-Giemsa stained smear and classified according to modified Feinendegen's classification, they were photographed. Then Wright-Giemsa stain was removed by immersion in 50% ethanol at 37 degrees C for 1 h and 100% methanol at 37 degrees C for 1 h. The specimens were then stained with DAPI solution (DAPI 0.01 mg/ml, pH 7.4 Tris-EDTA-2Na buffer solution and 0.01 M 2-mercaptoethylamine hydrochloride mixed at the ratio of 0.5:98.5:1.0) for more than 30 min. The amount of nuclear DNA in the previously identified megakaryocytes was measured by microcytofluorometry. The maximum population of megakaryocytes ploidy was in 16N in normal subjects, 8N in 10/12 MDS patients, and 4N in the remaining two patients. These findings suggest impairment of the development of the megakaryocytes nucleus in the MDS patients.
Insights
Myelodysplastic syndrome (MDS) impairs megakaryocyte nuclear DNA content. Normal subjects show 16N ploidy, while MDS patients exhibit reduced ploidy, indicating developmental abnormalities.
Area of Science:
- Hematology
- Cell Biology
- Genetics
Background:
- Megakaryocytes are crucial for platelet production.
- Myelodysplastic syndromes (MDS) are a group of clonal hematopoietic stem cell disorders characterized by ineffective hematopoiesis and increased risk of transformation to acute myeloid leukemia.
- Nuclear DNA content (ploidy) in megakaryocytes is a key indicator of their maturation and function.
Purpose of the Study:
- To determine and compare the nuclear DNA content (ploidy) of single megakaryocytes in normal subjects and patients with myelodysplastic syndrome (MDS).
- To investigate potential impairments in megakaryocyte nuclear development in MDS.
Main Methods:
- Megakaryocytes were identified and classified from Wright-Giemsa stained smears of normal subjects and MDS patients.
- Wright-Giemsa stain was removed, and cells were stained with DAPI (4',6-diamidino-2-phenylindole).
- Nuclear DNA content was measured using microcytofluorometry.
Main Results:
- Normal subjects exhibited a maximum megakaryocyte ploidy population of 16N.
- MDS patients showed a significantly reduced maximum ploidy, with 10 out of 12 patients at 8N and the remaining two at 4N.
- These results demonstrate a clear difference in megakaryocyte ploidy between normal individuals and those with MDS.
Conclusions:
- The study findings suggest that megakaryocyte nuclear development is impaired in patients with myelodysplastic syndrome.
- Reduced megakaryocyte ploidy in MDS indicates abnormal maturation processes.
- This research highlights a potential diagnostic or prognostic marker in MDS.